Allogene Therapeutics reports 31% response rate in Phase 1 trial
Allogene Therapeutics published Phase 1 data from the TRAVERSE study of ALLO-316 in advanced or metastatic renal cell carcinoma, showing a 31% confirmed response rate. The therapy demonstrated robust expansion, tumor infiltration, and durable antitumor activity. The trial is part of a five-year collaboration with The University of Texas MD Anderson Cancer Center.
*this image is generated using AI for illustrative purposes only.
Allogene Therapeutics, Inc. has published complete Phase 1 data from the TRAVERSE study of ALLO-316 in patients with advanced or metastatic renal cell carcinoma (RCC). The data, published in the Journal of Clinical Oncology, reveals a 31% confirmed response rate with the recommended Phase 2 regimen. The trial is part of a strategic five-year collaboration with The University of Texas MD Anderson Cancer Center.
ALLO-316 is a CD70-targeting AlloCAR T investigational therapy that incorporates the Dagger® technology. The therapy achieved robust expansion, tumor infiltration, and durable antitumor activity in a solid tumor setting. These findings highlight the potential of allogeneic CAR T products in treating solid tumors.
Key Trial Findings
The Phase 1 data demonstrated significant clinical activity for ALLO-316 in advanced or metastatic RCC. The confirmed response rate of 31% was observed with the recommended Phase 2 regimen. The therapy also showed robust expansion and tumor infiltration, which are critical for efficacy in solid tumors.
| Metric | Result |
|---|---|
| Confirmed Response Rate | 31% |
| Trial Phase | Phase 1 |
| Target Indication | Advanced or Metastatic RCC |
Collaboration and Technology
The TRAVERSE study is conducted as part of a strategic five-year collaboration with The University of Texas MD Anderson Cancer Center. ALLO-316 utilizes Allogene's proprietary Dagger® technology, designed to enhance the persistence and efficacy of AlloCAR T therapies. The publication of these results marks a significant milestone in the development of allogeneic CAR T products for solid tumors.
How will the 31% response rate influence the design and patient enrollment for the upcoming Phase 2 trial?
What competitive advantages does ALLO-316 offer over existing therapies for advanced or metastatic RCC?
How might the success of ALLO-316 impact Allogene's pipeline of allogeneic CAR T therapies for other solid tumors?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
